A5070879483- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Cancer Cells and Metastasis
- Prostate Cancer Diagnosis and Treatment
- FOXO transcription factor regulation
- Metabolism, Diabetes, and Cancer
- Intraperitoneal and Appendiceal Malignancies
- Genomics, phytochemicals, and oxidative stress
- Ovarian cancer diagnosis and treatment
- Statistical Methods in Clinical Trials
The Netherlands Cancer Institute
2020-2024
Oncode Institute
2020-2024
Reinier de Graaf Hospital
2017
Erasmus University Rotterdam
2015
PIK3CA, encoding the PI3Kα isoform, is most frequently mutated oncogene in estrogen receptor (ER)-positive breast cancer. Isoform-selective PI3K inhibitors are used clinically but intrinsic and acquired resistance limits their utility. Improved selection of patients that will benefit from these drugs requires predictive biomarkers. We show here persistent FOXM1 expression following drug treatment a biomarker to inhibition ER
Abstract Background The addition of adjuvant capecitabine to standard chemotherapy early-stage triple-negative breast cancer (TNBC) patients has improved survival in a few randomised trials and meta-analyses. However, many did not benefit. We evaluated the BRCA1 -like DNA copy number signature, indicative homologous recombination deficiency, as predictive biomarker for benefit TNBC subgroup FinXX trial. Methods Early-stage were between capecitabine-containing (TX + CEX:...
•Oncologists treat most eTNBC patients with chemotherapy due to a lack of implemented prognostic and predictive biomarkers.•We studied cohort systemic treatment-naïve young women node-negative 20 years median follow-up.•LVI (HR 2.35), fibrotic focus 1.61) sTILs 0.75 per 10% increment) had independent value for BCSS.•The presence LVI <30% identified an ultra-high risk recurrence or death.•De-escalation trials should consider the exclusion when is present. BackgroundIn absence biomarkers,...
Abstract Background Due to the abundant usage of chemotherapy in young triple-negative breast cancer (TNBC) patients, unbiased prognostic value BRCA1 -related biomarkers this population remains unclear. In addition, whether modify well-established stromal tumor-infiltrating lymphocytes (sTILs) is unknown. This study aimed compare outcomes young, node-negative, chemotherapy-naïve TNBC patients according status, taking sTILs into account. Methods We included 485 Dutch women diagnosed with...
Metronomic oral cyclophosphamide has gained increasing interest in recent years as a promising maintenance therapy advanced, platinum-sensitive, high-grade serous ovarian cancer (HGSOC). treatment with refers to the frequent, usually daily, administration of low (oral) dose no prolonged drug-free breaks. Main advantages this are effective reduction tumour activity, an outpatient setting, cost and toxicity profile. can benefit patients suffering from types known be sensitive alkylating...
Introduction: In this study, we estimated the time from first detectable prostate-specific antigen (PSA) following radical prostatectomy(RP) to commonly used definitions of biochemical recurrence (BCR). We also identified predictors BCR.Methods: subjects who underwent a RP and had an undetectable PSA after surgery followed by at least 1 between 2000 2011. The primary outcome was BCR (PSA ≥0.2 successive ≥0.2) prediction rate rise. Outcomes were calculated using competing risk analysis, with...
Abstract Background : Recent data demonstrate that patients with early-stage triple negative breast cancer (TNBC) benefit from escalating adjuvant treatment capecitabine. However, since a substantial proportion of does not benefit, predictive biomarkers to select those individuals upfront are needed. Over half all TNBCs have BRCA1 -like DNA copy number signature similar the profile found in germline -mutated cancers and indicative for homologous recombination deficiency. We evaluate this as...